Nicky Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicky Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ann Marie Pendergast
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
6 shared publications - Areej Abu Rmaileh
Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
6 shared publications - Benjamin Mayro
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710
6 shared publications - Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
6 shared publications - Gabriel Mesa
Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina
6 shared publications - Kerry Dillon
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1-7 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
- Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1-7 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
- Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts.Significance:This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts.See related commentary by Shen and Tan, p. 458
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts.Significance:This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts.See related commentary by Shen and Tan, p. 458
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1-7 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
- Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1-7 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
- Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.
- 19 November 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (3) , 595-615
PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts. Significance: This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts. See related commentary by Shen and Tan, p. 458
- 19 November 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (3) , 595-615
PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts. Significance: This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts. See related commentary by Shen and Tan, p. 458